[Treatment of chronic hepatitis with immunosuppressive agents and D-penicillamine].
D000380:Agranulocytosis / Q000139:chemically induced; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006501:Hepatic Encephalopathy / Q000139:chemically induced; D006505:Hepatitis / Q000188:drug therapy*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use*; D011507:Proteinuria / Q000139:chemically induced; D012621:Seasons; D013921:Thrombocytopenia / Q000139:chemically induced
D010396:Penicillamine; D001379:Azathioprine
Behandlung der chronischen Hepatitis mit Immunosuppressiva und D-Penicillamin.